

Bayer HealthCare AG Therapeutic and Drug Pipeline Review H2

Bayer HealthCare AG Treatment Pipeline Review H2 2017

PUNE, INDIA, February 2, 2017
/EINPresswire.com/ -- Summary
Bayer HealthCare AG (Bayer
Healthcare), a division of the Bayer
Group, is a healthcare company. It
designs, researches, develops,
manufactures and sells
pharmaceuticals and consumer health
products. The company provides
prescription pharmaceuticals, such as
anticoagulants; treatments for cancer,



hemophilia, multiple sclerosis, pulmonary hypertension, eye diseases, infectious diseases, high blood pressure and contraceptives; and over-the-counter (OTC) medications, nutritional supplements, dermatology products, veterinary medicines and animal grooming products, injection systems and contrast agents for diagnostic procedures. Bayer Healthcare markets its products across the world (including Europe, North America, Asia Pacific, Latin America, Africa and Middle East through regional and national distribution companies. Bayer Healthcare is headquartered in Leverkusen, Germany.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/918677-bayer-healthcare-ag-product-pipeline-analysis-2016-update □

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and

subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Bayer HealthCare AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table of Content: Key Points

Table of Contents 2

List of Tables 4

List of Figures 6

Bayer HealthCare AG Company Overview 7

Bayer HealthCare AG Company Snapshot 7

Bayer HealthCare AG Pipeline Products and Clinical Trials Overview 8

Bayer HealthCare AG - Pipeline Analysis Overview 10

Business Description 10

Key Facts 10

Bayer HealthCare AG - Major Products and Services 11

Bayer HealthCare AG Pipeline Products by Development Stage 13

Bayer HealthCare AG Pipeline Products Overview 16

AKT1/2 Inhibitor Based Companion Diagnostic Assay 16

AKT1/2 Inhibitor Based Companion Diagnostic Assay Product Overview 16

Analgesic Coated Silica Gel Fiber 17

Analgesic Coated Silica Gel Fiber Product Overview 17

Anetumab Ravtansine Based Companion Diagnostic Assay 18

Anetumab Ravtansine Based Companion Diagnostic Assay Product Overview 18

BET Inhibitor Based Companion Diagnostic Assay 19

BET Inhibitor Based Companion Diagnostic Assay Product Overview 19

C4.4a-ADC Based Companion Diagnostic Assay 20

C4.4a-ADC Based Companion Diagnostic Assay Product Overview 20

Ciprofloxacin Dry Powder Inhaler 21

...Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/918677-bayer-healthcare-ag-product-pipeline-analysis-2016-update

Get in touch:

LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: https://www.einpresswire.com/article/364786777

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.